Bio-Rad Laboratories, Inc.
BIOHealthcareNASDAQMedical Devices · Last scanned Sep 9, 2026
Scan Results
Daily timeframeBio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. The company carries a $10.16B market cap, placing it firmly in the large-cap category. It operates through two segments, Life Science and Clinical Diagnostics.
Market Cap
$10.16B
Beta
1.07
P/E (TTM)
46.24
P/E (Fwd)
37.91
EPS (TTM)
$8.22
EPS (Fwd)
$10.03
ROE
3.1%
ROA
1.7%
Cash
$1.62B
Total Debt
$1.37B
Free CF
$283.2M
52W Change
39.4%
Annual Financials
Cash vs Debt
Where BIO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BIO finished 30.50% above its 150-day moving average ($297.72) and 28.98% above its 200-day moving average ($301.22). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BIO overbought or oversold?
At the September 3, 2026 close, BIO's RSI(14) was 70.8, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Bio-Rad Laboratories, Inc. holds $1.62B in cash against $1.37B in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $283.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 3.1%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.7% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $2.80B (2022) to $2.58B (2025).
Investors considering Bio-Rad Laboratories, Inc. should weigh the typical risks associated with BIO's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing BIO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.